Vascular Endothelial Growth Factor-121, Recombinant, Human (VEGF-121)

Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as Tumor Angiogenesis Factor or Vascular Permeability Factor. Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating Vasolidation via nitric oxide-dependent pathways. Alternative splicing of the mRNA for VEGF-A results in several isoforms of the protein being produced. Rat and bovine VEGF are one amino acid shorter than the human factor, and the bovine and human sequences show a homology of 95 percent. In contrast to other factors mitogenic for endothelial cells such as FGF-1 , FGF-2 and PDGF, VEGF is synthesized as a precursor containing a typical hydrophobic secretory signal sequence of 26 amino acids. Glycosylation is not required for efficient secretion of VEGF.\n\nDescription: \nRecombinant Human VEGF-121 produced in insect cells is a double, non-glycosylated, polypeptide chain containing 121 amino acids and having a molecular mass of 28423 Dalton. VEGF121 circulates more freely than other VEGF forms, which bind more tightly with vascular heparin sulfates. Recombinant Human VEGF-121 is purified by proprietary chromatographic techniques.\n\nDimers and Aggregates: \nLess than 1% as determined by silver-stained SDS-PAGE gel analysis.\n\nBiological Activity: \nRecombinant Human VEGF-121 is fully biologically active when compared to standards. Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 0.2-0.4 ng/ml, corresponding to a Specific Activity of 5 x 105 IU/mg.\n\nEndotoxin: \n(same/less than) 0.1ng/ug (IEU/ug) of VEGF 121.\n\nProtein Content: \nProtein quantitation was carried out by two independent methods:\n1. UV spectroscopy at 280 nm.\n2. Analysis by RP-HPLC, using a calibrated solution of VEGF-121 as a Reference Standard.\n\nSolubility: \nIt is recommended to reconstitute the lyophilized Human VEGF-121 in sterile 18MOmega-cm H2O not less than 100microg/ml, which can then be further diluted to other aqueous solutions.\n\nStability: \nLyophilized Recombinant VEGF-121 although stable at room temperature for 3 weeks, should be stored desiccated below -180C. Upon reconstitution VEGF-121 should be stored at 40C between 2-7 days and for future use below -180C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

V2110-04S

Size

2ug

Form

Supplied as a lyophilized powder without additives.

Purity

(same/more than) 90% as determined by: \n(a) Analysis by RP-HPLC. \n(b) Anion-exchange FPLC. \n(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained gel.

References

1. Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma.\n\nLancet Oncol 2006 Jun;7(6):521-3\n\n2. VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice.\n\nMol Vis 2006 May 26;12:626-32\n\n3. Angiostatin decreases cell migration and vascular endothelium growth factor (VEGF) to pigment epithelium derived factor (PEDF) RNA ratio in vitro and in a murine ocular melanoma model.\n\nMol Vis 2006 May 22;12:511-7\n\n4. Signaling from across the way: transactivation of VEGF receptors by HSPGs.\n\nMol Cell 2006 May 19;22(4):431-2\n\n5. Phosphorylated Akt1 in human breast cancer measured by direct sandwich enzyme-linked immunosorbent assay: Correlation with clinicopathological features and tumor VEGF-signaling system component levels.\n\nInt J Biol Markers 2006 Jan-Mar;21(1):12-9\n\n6. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues.\n\nHistol Histopathol 2006 Aug;21(8):857-65